Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-cash Items (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Non-cash Items for 15 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • Quarterly Non-cash Items fell 4.38% to $2.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Sep 2025, down 4.38% year-over-year, with the annual reading at $1.9 million for FY2024, 6.21% up from the prior year.
  • Non-cash Items hit $2.1 million in Q3 2025 for Guided Therapeutics, down from $2.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $2.4 million in Q1 2025 to a low of -$224000.0 in Q2 2021.
  • Historically, Non-cash Items has averaged $1.7 million across 5 years, with a median of $1.9 million in 2023.
  • Biggest YoY gain for Non-cash Items was 127.81% in 2021; the steepest drop was 103.53% in 2021.
  • Year by year, Non-cash Items stood at -$224000.0 in 2021, then soared by 688.43% to $1.3 million in 2022, then skyrocketed by 37.42% to $1.8 million in 2023, then rose by 6.21% to $1.9 million in 2024, then rose by 7.98% to $2.1 million in 2025.
  • Business Quant data shows Non-cash Items for GTHP at $2.1 million in Q3 2025, $2.2 million in Q2 2025, and $2.4 million in Q1 2025.